Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21591449 | 0.87 | SMN1; SMN2 (0.35) | SMN1; SMN2CYP11B1CYP11B2ALDH1A1ALOX15 | |
| SCHEMBL21591439 | 0.85 | CYP11B1 (0.37) | SMN1; SMN2CYP11B1CYP11B2ALDH1A1ALOX15 | |
| SCHEMBL21591499 | 0.82 | CYP11B1 (0.51) | CYP11B1CYP11B2ALDH1A1MAPTCYP17A1 | |
| SCHEMBL21591514 | 0.81 | CYP11B1 (0.40) | CYP11B1CYP11B2ALDH1A1MAPTCYP17A1 | |
| SCHEMBL21591532 | 0.75 | CYP11B1 (0.39) | SMN1; SMN2CYP11B1CYP11B2ALDH1A1ALOX15 | |
| SCHEMBL21592292 | 0.74 | CYP11B1 (0.40) | SMN1; SMN2CYP11B1CYP11B2ALDH1A1ALOX15 | |
| SCHEMBL21591486 | 0.71 | — | — | |
| SCHEMBL21592278 | 0.71 | POLB (0.38) | CYP11B1CYP11B2ALDH1A1MAPTCYP17A1 | |
| SCHEMBL21591524 | 0.70 | CYP11B1 (0.53) | CYP11B1CYP11B2ALDH1A1CYP17A1CYP19A1 | |
| SCHEMBL21591521 | 0.69 | CYP11B1 (0.56) | CYP11B1CYP11B2ALDH1A1CYP17A1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402898-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2022-12-22 | — | — | US | disclosed |
| WO-2019238786-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2019-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402898-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | STING1, IRF3, CGAS | SMN1; SMN2 3753/4885CYP11B1 43/4885CYP11B2 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.